Literature DB >> 6139455

The involvement of 5-hydroxytryptamine in the release of dendritic dopamine from slices of rat substantia nigra.

J Williams, J A Davies.   

Abstract

[3H]dopamine (DA) accumulated by slices of rat substantia nigra was released following superfusion with Krebs solution containing 5-hydroxytryptamine (5-HT) in a dose-dependent fashion with maximal release being produced by 1 X 10(-4) M. This 5-HT-induced release of [3H]DA was calcium-dependent and was inhibited by pretreatment with the 5-HT antagonist cinanserin. These results are interpreted as supporting the possibility that 5-HT has a role in regulating dopaminergic activity in the nigro-striatal pathway.

Entities:  

Mesh：

Substances：

Year:  1983        PMID： 6139455     DOI： 10.1111/j.2042-7158.1983.tb02880.x

Source DB:  PubMed          Journal:  J Pharm Pharmacol        ISSN： 0022-3573            Impact factor:   3.765


  10 in total

1.  Striato-nigral dynorphin and substance P pathways in the rat. II. Functional analysis.

Authors:  M Herrera-Marschitz; I Christensson-Nylander; T Sharp; W Staines; M Reid; T Hökfelt; L Terenius; U Ungerstedt
Journal:  Exp Brain Res       Date:  1986       Impact factor: 1.972

2.  Sertraline and cocaine-induced locomotion in mice. I. Acute studies.

Authors:  M E Reith; H L Wiener; C T Fischette
Journal:  Psychopharmacology (Berl)       Date:  1991       Impact factor: 4.530

3.  Ultrastructural localization of the vesicular monoamine transporter-2 in midbrain dopaminergic neurons: potential sites for somatodendritic storage and release of dopamine.

Authors:  M J Nirenberg; J Chan; Y Liu; R H Edwards; V M Pickel
Journal:  J Neurosci       Date:  1996-07-01       Impact factor: 6.167

Review 4.  Presynaptic control of serotonin on striatal dopamine function.

Authors:  Sylvia Navailles; Philippe De Deurwaerdère
Journal:  Psychopharmacology (Berl)       Date:  2010-10-16       Impact factor: 4.530

5.  The influence of serotoninergic drugs on dopaminergic neurotransmission in rat substantia nigra, striatum and limbic forebrain in vivo.

Authors:  H Nissbrandt; N Waters; S Hjorth
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1992-07       Impact factor: 3.000

6.  A placebo-controlled trial of fluoxetine added to neuroleptic in patients with schizophrenia.

Authors:  D C Goff; K K Midha; O Sarid-Segal; J W Hubbard; E Amico
Journal:  Psychopharmacology (Berl)       Date:  1995-02       Impact factor: 4.530

7.  Decreased vigilance and neurotransmitter synthesis after discontinuation of dietary treatment for phenylketonuria in adolescents.

Authors:  H C Lou; F Güttler; C Lykkelund; P Bruhn; A Niederwieser
Journal:  Eur J Pediatr       Date:  1985-05       Impact factor: 3.183

8.  Ritanserin, a 5-HT2 receptor antagonist, activates midbrain dopamine neurons by blocking serotonergic inhibition.

Authors:  L Ugedo; J Grenhoff; T H Svensson
Journal:  Psychopharmacology (Berl)       Date:  1989       Impact factor: 4.530

9.  Prediction of schizophrenia using MAOA-uVNTR polymorphism: A case-control study.

Authors:  Jelena Culej; Nora Nikolac Gabaj; Mario Štefanović; Dalibor Karlović
Journal:  Indian J Psychiatry       Date:  2020-01-03       Impact factor: 1.759

10.  Perinatal interference with the serotonergic system affects VTA function in the adult via glutamate co-transmission.

Authors:  Catarina Cunha; John F Smiley; Nao Chuhma; Relish Shah; Cynthia Bleiwas; Edenia C Menezes; Rebecca P Seal; Robert H Edwards; Stephen Rayport; Mark S Ansorge; Francisco X Castellanos; Catia M Teixeira
Journal:  Mol Psychiatry       Date:  2020-05-12       Impact factor: 15.992
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.